Fitusiran Delay Dents Sanofi’s Hemophilia Challenge
Company Still Aiming For Universal Therapy
Executive Summary
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.
You may also be interested in...
Sanofi Continues Hunt For External Innovation With Skyhawk Deal
Deal Snapshot: A lot of the French drug maker’s interest has focused on biologics, but the Skyhawk deal shows it has maintained a keen interest in innovative small molecules as well.
As BioMarin Stumbles, Sanofi Gets Breakthrough Status For Hemlibra Challenger
Sanofi and its partner Sobi believe they have the future “Factor VIII of choice” t could also challenge the dominance of Roche’s Hemlibra.
Sanofi Looks To Dominate $5bn Hemophilia A Factor Market After Trial Success
Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.